Navigation Links
Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/10/2010

BOSTON, Sept. 10 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, PTK 0796, a first-in-class aminomethylcycline, will be the subject of several poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  Dr. Stuart Levy, co-founder and Chief Scientific Officer of Paratek will also be delivering a talk at a symposium on antibiotic resistance at the conference.  ICAAC will be held in Boston, Massachusetts from September 12 - September 15, 2010.

More information on the poster sessions and symposium at ICAAC:Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDTSession 002; Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents

Location: Exhibit Hall B1

Poster:  A1-022, Board#19


  • Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic.

  • Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDTSession 004; Antibiotic Therapy of Vascular Infections in Animal Models

    Location: Exhibit Hall B1

    Poster:  B-069, Board#70


  • Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model.

  • Sunday, September 12, 4:00 p.m.– 4:50 p.m. EDTSession 032; How 50 Years of Antibacterial Drug Development has Been Driven by Antibiotic Resistance

    Location: Room 052A

    Presentation:  456

    Presenter:  Stuart B. Levy, M.D.


  • A Tetracycline Renaissance.

  • Tuesday, September 14, 11:15 a.m.- 1:15 p.m. EDTSession 169; Antibiotic Resistance in Gram-Negative Bacteria Other than Enterobacteriacea

    Location: Exhibit Hall B1

    Poster:  C1-1413, Board#68


  • Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 176; Anti-Staphylococcal Agents:  In Vitro/In Vivo Efficacy

    Location: Exhibit Hall B1

    Poster:  E-1569, Board#232


  • In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 177; In Vitro Efficacy of Antimicrobials against Gram-Positive Bacteria

    Location: Exhibit Hall B1

    Poster:  E-1588, Board#254


  • Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 191; Treatment Issues in Gram-Positive Infections

    Location: Exhibit Hall B1

    Poster:  L1-1760, Board#445


  • Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI):  Results of a PTK 0796 (PTK) Phase 2 Clinical Trial.
  • About Paratek PharmaceuticalsParatek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance.  Paratek is advancing novel compounds that can circumvent or block bacterial resistance.  Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae).  Oral and IV formulations of PTK 0796 were compared to Zyvox ® in a Phase 2 clinical study in complicated skin and skin structure infections (cSSSI).  In addition to PTK 0796, Paratek is also developing other tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

    Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial tetracycline derivatives with improved activity in serious inflammatory and neurodegenerative diseases.  In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in spinal muscular atrophy (SMA).  Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

    Paratek has active collaborations with Novartis, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for a range of uses, including bacterial infections, acne & rosacea and SMA.  Paratek is privately held and headquartered in Boston, Massachusetts, USA.  For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.


    '/>"/>

    SOURCE Paratek Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
    3. Martek to Present at Upcoming UBS Conference
    4. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
    5. Kendle to Present at Robert W. Baird & Co. 2010 Health Care Conference
    6. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
    7. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
    8. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    9. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
    10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
    11. The Female Health Company to Present at Rodman & Renshaws Annual Global Investment Conference on Wednesday, September 15, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
    (Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
    (Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
    (Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
    Breaking Biology Technology:
    (Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
    (Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
    (Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
    Breaking Biology News(10 mins):